N
CTKB icon

Numerai’s Cytek Biosciences CTKB Stock Holding History

Numerai’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$491K Sell
112,460
-74,304
-40% -$351K 0.05% 523
2025
Q4 		$943K Buy
186,764
+80,269
+75% +$373K 0.11% 258
2025
Q3 		$370K Sell
106,495
-315,823
-75% -$1.19M 0.05% 396
2025
Q2 		$1.44M Buy
+422,318
New +$1.41M 0.21% 142

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Numerai's CTKB Position: Q1 2026 in Review

Numerai reduced its Cytek Biosciences (CTKB) stake by 40% in Q1 2026, selling an estimated $351K and leaving 112,460 shares worth $491K. The position accounts for 0.05% of the portfolio, ranked #523.

Numerai first reported a position in CTKB in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.44M in Q2 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Numerai held 112,460 shares of Cytek Biosciences worth $491K as of Q1 2026.
  • Numerai sold 74,304 Cytek Biosciences shares in Q1 2026, an estimated $351K.
  • Cytek Biosciences made up 0.05% of Numerai's portfolio in Q1 2026, its #523 holding.
  • Numerai first reported a position in Cytek Biosciences in Q2 2025 and has held it in 4 quarters since.
  • Numerai's Cytek Biosciences position peaked at $1.44M in Q2 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Numerai's 13F filing for Q1 2026, filed 15 May 2026.